Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent

Cancer

Volumn 106, Issue 8, 2006, Pages 1804-1814

  Boulos, David L ^a   Groome, Patti A ^a   Brundage, Michael D ^a   Siemens, D Robert ^b   Mackillop, William J ^a   Heaton, Jeremy P W ^b   Schulze, Karleen M ^a   Rohland, Susan L ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Comorbidity; Health status indicators; Predictive value of tests; Prostatic neoplasms; Reproducibility of results; Survival rate

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CHARLSON INDEX; CHRONIC DISEASE SCORE; CLINICAL RESEARCH; COMORBIDITY; CONFIDENCE INTERVAL; CUMULATIVE ILLNESS RATING SCALE; HUMAN; INDEX OF COEXISTENT DISEASE; KAPLAN FEINSTEIN INDEX; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CARCINOMA; RATING SCALE; SOCIAL STATUS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33646066333     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21813     Document Type: Article

References (44)

1. Last JM. A dictionary of epidemiology. New York: Oxford University Press; 1988.
2. Schrijvers CT, Coebergh JW, Mackenbach JP. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer. 1997;80:1482-1488.
3. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
4. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. JAMA. 1996;156:127-132.
5. Goldenberg SL, Ramsey EW, Jewett MAS. Prostate cancer: 6. Surgical treatment of localized disease JO. Can Med Assoc J. 1998;159:1381-1388.
6. Dodds TA, Martin DP, Stolov WC, Deyo RA. A validation of the functional independent measurement and its performance among rehabilitation inpatients. Arch Phys Med Rehabil. 1993;74:531-536.
7. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
8. Warde P, Catton C, Gospodarowicz MK. Prostate cancer: 7. Radiation therapy. Can Med Assoc J. 1998;159:1381-1388.
9. British Columbia Cancer Agency. Cancer management manual. Available at URL:http://www.bccancer.bc.ca [accessed March 15, 2005].
10. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626-631.
11. Ross AS, Grant M. Experimental and nonexperimental designs in social psychology. Boulder, CO: Westview Press; 1996.
12. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
13. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care. 1993;31:141-154.
14. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41:237-248.
15. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluation the outcome of diabetes mellitus. J Chronic Dis. 1974;27:387-404.
16. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-1587.
17. Singh B, Bhaya M, Zimbler M, et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck. 1998;20:1-7.
18. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000;110:593-602.
19. Newschaffer CJ, Bush TL, Penberthy LT. Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. J Clin Epidemiol. 1997;50:725-733.
20. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002;123:280-287.
21. West DW, Satariano WA, Ragland DR, Hiatt RA. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol. 1996;6:413-419.
22. Singh B, Bhaya M, Stern J, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope. 1997;107:1469-1475.
23. Sabin SL, Rosenfeld RM, Sundaram K, Har-El G, Lucente FE. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J. 1999;78:578-4.
24. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73:1-11.
25. Mackillop W, Zhang-Salomons J, Groome P, Paszat L, Holowaty E. Socioeconomic status and cancer survival in Ontario. J Clin Oncol. 1997;15:1680-1689.
26. Agresti A. Categorical data analysis. New York: John Wiley & Sons, 1990.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
28. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50:1064-1072.
29. Self SG, Prentice RL. Asymptotic distribution theory and efficiency results for case-cohort studies. Ann Stat. 1988;16:64-81.
30. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52:1165-1172.
31. Lin DY, Ying Z. Cox regression with incomplete covariate measurement. J Am Stat Assoc. 1993;88:1341-1349.
32. Schemper M. Further results on the explained variation in proportional hazards regression. Biometrika. 1992;79:202-204.
33. Schemper M. The relative importance of prognostic factors in studies of survival. Stat Med. 1993;12:2377-2382.
34. Wacholder S, Gail MH, Pee D, Brookmeyer R. Alternative variance and efficiency calculations for the case-cohort design. Biometrika. 1989;76:117-123.
35. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65-70.
36. Miller RG. Simultaneous statistical inference. New York: McGraw-Hill, 1966.
37. SAS Institute, Inc.. SAS software: changes and enhancements, release 6.10. Cary, NC: SAS Institute Inc., 1994:1-184.
38. Therneau TM, Li H. Computing the Cox model for case-cohort designs. Technical Report 62. Rochester, MN: Mayo Clinic, 1998.
39. Gronberg H, Damber JE, Jonsson H, Lenner P. Patient age as a prognostic factor in prostate cancer. JAMA. 1994;152:892-895.
40. Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA. 1987;257:2766-2770.
41. Greenfleld S, Aronow HU, Elashoff RM, Watanabe D. Flaws in mortality data. The hazards of ignoring comorbid disease. JAMA 1988;260:2253-2255.
42. The Federal, Provincial and Territorial Advisory Committee on Population Health. Toward a health future: second report on the health of Canadians. Ottawa, Ontario, Canada: Public Works and Government Services Canada; 1999:1-224.
43. Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998;83:1180-1188.
44. Schwartz M, Iezzoni LI, Moskowitz MA, Ash AS, Sawitz E. The importance of comorbidities in explaining differences in patient costs. Med Care. 1996;34:767-782.